PARSIPPANY, N.J. / May 14, 2024 / Business Wire / Zoetis Inc. (NYSE:ZTS) has been named to Fair360’s Top 50 Companies list for the first time, underscoring the company’s progress and sustained commitment to advancing Diversity, Equity and Inclusion (DE&I). Zoetis is the only animal health company included in this year’s Top 50 rankings.
“Zoetis’ DE&I focus begins with our dedicated Board of Directors and executive team of diverse experiences, backgrounds, and perspectives, promoting an inclusive environment for all colleagues at all levels,” said Evelyn Ortiz, Chief Talent, Diversity & Inclusion Officer at Zoetis. "We are extremely proud of our progress advancing inclusion within our company and the animal health industry and are committed to driving positive change into the future.”
Highlights of Zoetis’ application for the Fair360 Top 50 ranking include:
The Fair360, formerly DiversityInc., Top 50 survey has been the external validator for large U.S. employers that model fairness in their talent strategies, workplace and supplier diversity practices and philanthropic engagement since 2001. This year, 160 employers, collectively representing 7.3 million U.S. employees, submitted comprehensive data and metrics on leadership accountability, human capital diversity, talent programs, workplace practices, supplier diversity and philanthropy.
Additional honors for Zoetis
Zoetis was honored at the Fair360 Top 50 event in New York City last night, which focused on the theme, “bridging DE&I and strategic business.” At the event, Zoetis was also recognized on three Fair360 specialty lists, including Top Companies for Women Executives, Top Companies for Latino Executives and Top Companies for Talent Acquisition for Women of Color.
Learn more
To learn more about Zoetis’ award-winning culture, visit www.zoetis.com/join-us. More information about the Fair360 Top 50 Companies Award can be found here.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.
About Fair360
Fair360, formerly known as DiversityInc., leverages comparative human capital data to help organizations develop fair and inclusive workplaces utilizing benchmarking and best practices. Its mission is to provide committed leaders with insights to drive an effective workforce planning strategy, ensuring equity for all employees. Fair360 is a VA-certified and veteran-owned business. It is certified by Disability:IN as a company owned by a person with a disability. For more information, visit the Fair360 website, X (formerly known as Twitter), Facebook and LinkedIn. For more information about the overall model with a Cronbach Alpha Reliability score of .93, visit www.Fair360.com/Methodology.
Last Trade: | US$175.67 |
Daily Change: | 0.11 0.06 |
Daily Volume: | 2,106,495 |
Market Cap: | US$79.260B |
November 04, 2024 September 26, 2024 August 06, 2024 May 02, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB